During a busy day of dealmaking, Cour Pharmaceutical Development Co. Inc. entered a pact with Roche Holding AG’s Genentech unit to advance tolerogenic nanoparticle treatments for an autoimmune disease indication, garnering up to $940 million in up-front and milestone payments. Cour’s partnership with Genentech is its biggest to date, and the largest deal announced by a biopharma company on Dec. 3. A total of seven deals amounted to a combined single-day deal value of $3.67 billion. Read More
Janux Therapeutics Inc. CEO David Campbell said the firm will be talking with the U.S. FDA about “what we may or may not be able to do [in order to get JANX-007] to patients more rapidly,” though he noted that the agency has “primarily been focused on overall survival” in considering prostate cancer drugs, so more work on that endpoint may be required. “We’ll keep that in mind,” he said. Read More
Tubulis GmbH has sealed a potential $415 million option and licensing deal under which it will apply proprietary technologies to discover an antibody-drug conjugate (ADC) against a solid tumor target for Gilead Sciences Inc. Read More
After raising AU$40 million (US$25.9 million) earlier this year to advance lead candidate VP-001 for treating retinitis pigmentosa type 11, PYC Therapeutics is now advancing PYC-003 to the clinic for polycystic kidney disease. Read More
South Korean billionaire and chairman of Celltrion Group Jungjin Seo is returning Celltrion Inc. to its contract manufacturing organization (CMO) roots, as it relies on biosimilar sales to anchor the company in a fiercely competitive novel drug R&D arena. Read More
Kiromic Biopharma Inc. and two former senior officials have settled with the U.S. SEC to resolve charges involving nondisclosure of U.S. FDA clinical holds on two cancer candidates before and after a July 2021 follow-on public offering that raised $40 million the company desperately needed. Read More
The congressional finger-pointing at pharmacy benefit managers (PBMs) continues. The latest singling out is in a bipartisan letter from four House members calling on the U.S. Department of Justice to investigate and hold PBMs accountable for the role they played in the nationwide opioid crisis. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Autolus, Galderma, Gilead, Hua, Maplight, Merus, MBX, Revolution Medicines, Senti, Soligenix. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alligator, Atom, China Medical Systems, Hepion, Medac, Medexus, Merus, Partner, Pharma Two B, Pulmokine, Sernova, Xoma. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aavantgarde, Applied Therapeutics, Biocon, Bluebird, Cytokinetics, Everest Medicines, Johnson & Johnson, Pfizer, PTC, Rigel, Sana, Stallergenes, Travere. Read More
